FTC's Health Care Reform Plan: Save $12 Billion With Reverse Settlement Ban

The Federal Trade Commission has drawn another arrow in its attempt to shoot down reverse settlements between brand and generic drug companies - offering an estimate of $12 billion in government savings over the next 10 years from ending the practice

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet